Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,598 | -1,250 | 95 | -104 | -2,629 |
| Depreciation Amortization | 153 | 110 | 61 | 30 | 108 |
| Accounts receivable | 148 | 151 | -3 | -113 | 651 |
| Accounts payable and accrued liabilities | 204 | -258 | -458 | 55 | -381 |
| Other Working Capital | 115 | -323 | -322 | 4 | 118 |
| Other Operating Activity | -1,116 | -742 | -82 | 90 | 311 |
| Operating Cash Flow | $-2,093 | $-2,313 | $-709 | $-37 | $-1,822 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -227 | -223 | -24 | -22 | -149 |
| Purchase Of Investment | -493 | -486 | -265 | -174 | -321 |
| Sale Of Investment | 1,069 | 495 | 298 | 211 | 26 |
| Other Investing Activity | 69 | 78 | 58 | -12 | -1,350 |
| Investing Cash Flow | $418 | $-136 | $67 | $4 | $-1,794 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | N/A | N/A | 5,750 |
| Other Financing Activity | 4 | 146 | 202 | 27 | 525 |
| Financing Cash Flow | $4 | $146 | $202 | $27 | $6,275 |
| Exchange Rate Effect | 40 | 450 | -115 | -72 | -260 |
| Beginning Cash Position | 4,518 | 4,518 | 4,518 | 4,518 | 2,119 |
| End Cash Position | 2,887 | 2,665 | 3,962 | 4,439 | 4,518 |
| Net Cash Flow | $-1,631 | $-1,852 | $-556 | $-79 | $2,399 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,093 | -2,313 | -709 | -37 | -1,822 |
| Capital Expenditure | -227 | -223 | -24 | -22 | -149 |
| Free Cash Flow | -2,320 | -2,536 | -733 | -59 | -1,972 |